The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.
In this roundtable discussion on myeloma and CELMoDs, the panel discuss mechanism of action, overcoming drug resistance, and other distinguishing features of this novel group of treatment agents.
Dr. Dimopoulos reviews the clinical efficacy of adding the novel cereblon E3 ligase modulator (CELMoD), mezigdomide, to carfilzomib and dexamethasone (MeziKd) for patients with relapsed or refractory multiple myeloma, explaining how this combination significantly extends progression-free survival timelines for an increasingly high-risk, triple-class-exposed population.
The nanobody-based CD5 CAR T-cells had superior antigen-dependent activation compared with humanized CD5 CAR T-cells, said lead author, Jing Pan, MD, PhD, of Chinese Academy of Medical Sciences and Peking Union Medical College in Tianjin, China.
The NMPA approval was based on data from the phase 2 ROCK-1 study evaluating rocbrutinib monotherapy in patients with MCL who had relapsed or were refractory after prior treatment with covalent BTK inhibitors. As of June 5, 2025, clinical trial data showed an objective response rate of 63.9%, a complete response rate of 23%, and a median duration of response of 16.5 months.
Claire Harrison, MD, deputy chief medical officer at the Guy’s and St. Thomas’ NHS Foundation in the United Kingdom, discusses results from the phase 1 trial of INCA033989 in CALR-mutant myelofibrosis, which were presented at the 2026 European Hematology Association Congress in Stockholm, Sweden.
The clinical approval was based on data from the international phase 2 L-MIND trial and the domestic phase 1b/2 J-MIND trial in Japan. In the international study, patients treated with the tafasitamab combination achieved an overall response rate of 58.8% with a 41.3% complete response rate.
SOHO Insider is the official media platform of the Society of Hematologic Oncology. The SOHO Insider Editorial Board is comprised of leading hematologists. Learn more about our editorial board and SOHO Insider platforms.
To access the SOHO Career Center click the following link.
![Insider_YT_Feature_Pannunzio_CLFR2_400x400[15]](https://sohoinsider.com/wp-content/uploads/2026/06/Insider_YT_Feature_Pannunzio_CLFR2_400x40015.png)
